NCT02545751Unknown2 期
A Phase II Study of Stereotactic Body Radiation Therapy and ZADAXIN's® (Thymalfasin) Induced Tumor Effects in Patients With Heavily Pretreated, Metastatic Esophageal Cancer
Hangzhou Cancer Hospital1 个研究点 分布在 1 个国家目标入组 29 人开始时间: 2016年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 29
- 试验地点
- 1
- 主要终点
- The proportion of patients with tumor responses after the initiation of treatment.
研究概览
简要总结
Patients with esophageal cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study.
- To observe immunity-mediated tumor response after Stereotactic Body Radiation Therapy(SBRT) of a metastatic site in metastatic esophageal cancer patients.
- To induce the efficacy (effectiveness) of a new combination of therapy, SBRT and thymalfasin for heavily pretreated, metastatic esophageal cancer patients; This study will help find out what effects (good or bad) the combination of radiotherapy and thymalfasin has on metastatic esophageal cancer.
详细描述
- To observe immunity-mediated tumor response after Stereotactic Body Radiation Therapy(SBRT) of a metastatic site in metastatic esophageal cancer patients.
- To induce the efficacy (effectiveness) of a new combination of therapy, SBRT and thymalfasin for heavily pretreated, metastatic esophageal cancer patients; Eligible are patients with metastatic esphageal cancer who have achieved stable disease or have disease progression after systemic therapy (surgery or definitive chemoradiotherapy) and have at least two measurable sites of metastatic lesions. Extent of metastatic disease is recorded both at CT and PET/CT scanning. Radiation is given during combined therapy to one of the lesions, 25Gy in 5 fractions over one week interval with SBRT, conformally to maximally spare normal tissue or organ. Thymalfasin treatment is given twice a week with an interval of 3-4 days each week for a total of 8 weeks. Tumor response is evaluated by assessing clinical and CT/MRI response for all of the measurable metastatic sites. A Phase II clinical trial based on an optimum two-stage Phase II Simon design is used to conduct this pilot study. Ten patients will be treated in Stage one; if there are no tumor responses, the trial will be terminated. If there are one or more tumor responses in Stage One, the trial will proceed to enroll an additional 19 patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically confirmed esophageal cancer which is persistent and metastatic or recurrent and metastatic;
- •Patients must have at least 2 distinct measurable metastatic sites at least 1 cm of larger in their largest diameter;
- •Age ≥18 years;
- •Metastatic disease measurable on a CT/MRI scan. The primary tumor is not considered measurable disease. Metastatic lesions within a prior radiation field are acceptable as long as disease has progressed in the radiation field by RECIST criteria. The same imaging modality performed at baseline (CT or MRI) will be repeated at subsequent imaging.
- •ECOG performance status: 0-1;
- •Life expectancy ≥ 3 months.
- •Patients have adequate baseline organ and marrow function as defined by an absolute neutrophil count greater than 1500 cells per μL, platelet concentration of greater than 50 000 per μL, total bilirubin less than 1•5 times the upper limit of normal (ULN), aspartate aminotransferase and alanine aminotransferase less than 2•5 times the ULN, and serum creatinine less than 1•5 times the ULN;
- •Signed consent forms voluntarily;
排除标准
- •Patients undergoing therapy with other investigational agents.
- •Women who are pregnant or breastfeeding;
- •Patients with known brain metastases can be included in this clinical trial but brain lesions are not eligible as target or non target lesion;
- •Anticipated patient survival under 3 months;
- •Active severe infection or known chronic infection with HIV, hepatitis B virus, or hepatitis C virus;
- •Cardiovascular disease problems including unstable angina, therapy for life-threatening ventricular arrhythmia, myocardial infarction, stroke or congestive heart failure within the last 6 months;
- •The subject has had another active malignancy within the past five years except for cervical cancer in site, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin;
- •Clinically significant and uncontrolled major medical conditions including but not limited to: active uncontrolled infection, symptomatic congestive heart failure, Unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation that would limit compliance with study requirements; any medical condition, which in the opinion of the study investigator places the subject at an unacceptably high risk for toxicities;
- •Patients with any other concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for participation in the study.
研究组 & 干预措施
SBRT and Thymalfasin arm
Experimental
SBRT is given during combined therapy to one of the lesions, 25Gy in 5 fractions over one week, conformally to maximally spare normal tissue or organ. Thymalfasin treatment is given twice a week with an interval of 3-4 days until tumor progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
干预措施: Stereotactic Body Radiation Therapy (Radiation)
SBRT and Thymalfasin arm
Experimental
SBRT is given during combined therapy to one of the lesions, 25Gy in 5 fractions over one week, conformally to maximally spare normal tissue or organ. Thymalfasin treatment is given twice a week with an interval of 3-4 days until tumor progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
干预措施: Thymalfasin (Drug)
结局指标
主要结局
The proportion of patients with tumor responses after the initiation of treatment.
时间窗: month 1- month 6
次要结局
- The proportion of patients alive with tumor responses from the date of enrollment until date of death from any cause, assessed up to 2 years from the opening of the study.(year 0- year 2)
- The number of participants with adverse events from the date of enrollment until 2 years from the opening of the study.(year 0- year 2)
研究者
Shixiu Wu
MD
Hangzhou Cancer Hospital
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Stereotactic Body Radiotherapy for Oligometastases From Colorectal CancerColorectal CancerNCT02909114Jing Jin, M.D.50
已完成
不适用
Concurrent Chemoradiotherapy With Docetaxel and Cisplatin in Esophageal CancerEsophageal CancerNCT01640860Chonnam National University Hospital36
招募中
2 期
Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus ChemotherapyEsophageal Neoplasm MetastaticEsophageal Cancer Stage IVbNCT06084897Cancer Institute and Hospital, Chinese Academy of Medical Sciences120
已完成
不适用
Radiotherapy for Oligometastatic Prostate CancerOligometastatic Prostate CancerNCT01859221University of Florida39
已完成
不适用
Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central AirwaysLung CancerNCT01051037Jonsson Comprehensive Cancer Center17